This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Clercq, E.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, Oct 1997, 674-693, Vol 10, No. 4
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

In search of a selective antiviral chemotherapy

E De Clercq
Rega Institue for Medical Research, Katholieke Universiteit Leuven, Belgium.

This article describes several approaches to a selective therapy of virus infections: (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU [brivudin]) for the therapy of herpes simplex virus type 1 and varicella-zoster virus infections: (S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine (HPMPC [cidofovir]) for the therapy of various DNA virus (i.e., herpesvirus, adenovirus, papillomavirus, polyomavirus, and poxvirus) infections; 9-(2- phosphonylmethoxyethyl)adenine (PMEA [adefovir]) for the therapy of retrovirus, hepadnavirus, and herpesvirus infections; (R)-9-(2- phosphonylmethoxypropyl)adenine (PMPA) for the therapy and prophylaxis of retrovirus and hepadnavirus infections; and nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as tetrahydroimidazo[4,5,1- jk][1,4]-benzodiazepin-2(IH)-one and -thione (TIBO), 1-[(2- hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), alpha- anilinophenylacetamide (alpha-APA), and 2',5'bis-O-(tert- butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxat hiole- 2",2"- dioxide)pyrimidine (TSAO) derivatives, and thiocarboxanilides for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. For the clinical use of NNRTIs, some guidelines have been elaborated, such as starting treatment with combinations of different compounds at sufficiently high concentrations to effect a pronounced and sustained suppression of the virus. Despite the diversity of the compounds described here and the different viruses at which they are targeted, they have a number of characteristics in common. As they interact with specific viral proteins, the compounds achieve a selective inhibition of the replication of the virus, which, in turn, should be able to develop resistance to the compounds. However, as has been established for the NNRTIs, the problem of viral resistance may be overcome if the compounds are used from the start at sufficiently high doses, which could be reduced if different compounds are combined. For HIV infections, drug treatment regimens should be aimed at reducing the viral load to such an extent that the risk for progression to AIDS will be minimized, if not avoided entirely. This may result in a real "cure" of the disease but not necessarily of the virus infection, and in this sense, HIV disease may be reduced to a dormant infection, reminiscent of the latent herpesvirus infections. Should virus replication resume after a certain time, the armamentarium of effective anti-HIV and anti- herpesvirus compounds now available, if applied at the appropriate dosage regimens, should make the virus return to its dormant state before it has any chance to damage the host. It is unlikely that this strategy would eradicate the virus and thus "cure" the viral infection, but it definitely qualifies as a cure of the disease.


This article has been cited by other articles:

  • Snoeck, R., Holy, A., Dewolf-Peeters, C., Van Den Oord, J., De Clercq, E., Andrei, G. (2002). Antivaccinia Activities of Acyclic Nucleoside Phosphonate Derivatives in Epithelial Cells and Organotypic Cultures. Antimicrob. Agents Chemother. 46: 3356-3361 [Abstract] [Full Text]  
  • Ray, A. S., Basavapathruni, A., Anderson, K. S. (2002). Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir. J. Biol. Chem. 277: 40479-40490 [Abstract] [Full Text]  
  • Biron, K. K., Harvey, R. J., Chamberlain, S. C., Good, S. S., Smith, A. A. III, Davis, M. G., Talarico, C. L., Miller, W. H., Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., Townsend, L. B., Koszalka, G. W. (2002). Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole L-Riboside with a Unique Mode of Action. Antimicrob. Agents Chemother. 46: 2365-2372 [Abstract] [Full Text]  
  • Balzarini, J., Pannecouque, C., De Clercq, E., Aquaro, S., Perno, C.-F., Egberink, H., Holy, A. (2002). Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates. Antimicrob. Agents Chemother. 46: 2185-2193 [Abstract] [Full Text]  
  • Leblond, L., Attardo, G., Hamelin, B., Bouffard, D. Y., Nguyen-Ba, N., Gourdeau, H. (2002). BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: A Cyclic Nucleoside Phosphonate with Antitumor Activity. Molecular Cancer Therapeutics 1: 737-746 [Abstract] [Full Text]  
  • Yoshimura, K., Kato, R., Kavlick, M. F., Nguyen, A., Maroun, V., Maeda, K., Hussain, K. A., Ghosh, A. K., Gulnik, S. V., Erickson, J. W., Mitsuya, H. (2002). A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site. J. Virol. 76: 1349-1358 [Abstract] [Full Text]  
  • Sienaert, R., Naesens, L., Brancale, A., De Clercq, E., McGuigan, C., Balzarini, J. (2002). Specific Recognition of the Bicyclic Pyrimidine Nucleoside Analogs, a New Class of Highly Potent and Selective Inhibitors of Varicella-Zoster Virus (VZV), by the VZV-Encoded Thymidine Kinase. Mol. Pharmacol. 61: 249-254 [Abstract] [Full Text]  
  • Murono, S., Raab-Traub, N., Pagano, J. S. (2001). Prevention and Inhibition of Nasopharyngeal Carcinoma Growth by Antiviral Phosphonated Nucleoside Analogs. Cancer Res. 61: 7875-7877 [Abstract] [Full Text]  
  • KRYNETSKAIA, N. F., FENG, J. Y., KRYNETSKI, E. Y., GARCIA, J. V., PANETTA, J. C., ANDERSON, K. S., EVANS, W. E. (2001). Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB J. 15: 1902-1908 [Abstract] [Full Text]  
  • Liekens, S., Neyts, J., De Clercq, E., Verbeken, E., Ribatti, D., Presta, M. (2001). Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir. Cancer Res. 61: 5057-5064 [Abstract] [Full Text]  
  • De Clercq, E. (2001). Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections. Clin. Microbiol. Rev. 14: 382-397 [Abstract] [Full Text]  
  • Li, Q., Boyer, C., Lee, J. Y., Shepard, H. M. (2001). A Novel Approach to Thymidylate Synthase as a Target for Cancer Chemotherapy. Mol. Pharmacol. 59: 446-452 [Abstract] [Full Text]  
  • Lee, K., Chu, C. K. (2001). Molecular Modeling Approach to Understanding the Mode of Action of L-Nucleosides as Antiviral Agents. Antimicrob. Agents Chemother. 45: 138-144 [Abstract] [Full Text]  
  • Vaccaro, J. A., Parnell, K. M., Terezakis, S. A., Anderson, K. S. (2000). Mechanism of Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by d4TTP: an Equivalent Incorporation Efficiency Relative to the Natural Substrate dTTP. Antimicrob. Agents Chemother. 44: 217-221 [Abstract] [Full Text]  
  • FENG, J. Y., SHI, J., SCHINAZI, R. F., ANDERSON, K. S. (1999). Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 13: 1511-1517 [Abstract] [Full Text]  
  • Uchida, H., Kodama, E. N., Yoshimura, K., Maeda, Y., Kosalaraksa, P., Maroun, V., Qiu, Y.-L., Zemlicka, J., Mitsuya, H. (1999). In Vitro Anti-Human Immunodeficiency Virus Activities of Z- and E-Methylenecyclopropane Nucleoside Analogues and Their Phosphoro-L-Alaninate Diesters. Antimicrob. Agents Chemother. 43: 1487-1490 [Abstract] [Full Text]  
  • Cannon, J. S., Hamzeh, F., Moore, S., Nicholas, J., Ambinder, R. F. (1999). Human Herpesvirus 8-Encoded Thymidine Kinase and Phosphotransferase Homologues Confer Sensitivity to Ganciclovir. J. Virol. 73: 4786-4793 [Abstract] [Full Text]  
  • Cohen, J. I., Brunell, P. A., Straus, S. E., Krause, P. R. (1999). Recent Advances in Varicella-Zoster Virus Infection. ANN INTERN MED 130: 922-932 [Abstract] [Full Text]  
  • McSharry, J. J., Lurain, N. S., Drusano, G. L., Landay, A. L., Notka, M., O'Gorman, M. R. G., Weinberg, A., Shapiro, H. M., Reichelderfer, P. S., Crumpacker, C. S. (1998). Rapid Ganciclovir Susceptibility Assay Using Flow Cytometry for Human Cytomegalovirus Clinical Isolates. Antimicrob. Agents Chemother. 42: 2326-2331 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»